# Balchem Corp: financial statements, quarterly

BCPC · Nasdaq · CIK 9326 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bcpc.md) · [Financials](/companies/bcpc/financials.md) · [Filings](/companies/bcpc/filings.md) · [Insiders](/companies/bcpc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bcpc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [229](/filings/0001628280-25-007202.md) | [240](/filings/0000009326-26-000007.md) | [234](/filings/0000009326-26-000007.md) | [240](/filings/0000009326-26-000007.md) | [240](/filings/0000009326-26-000007.md) | [251](/filings/0000009326-26-000018.md) | [255](/filings/0000009326-26-000028.md) | [268](/filings/0000009326-26-000035.md) | [264](/filings/0000009326-26-000007.md) | [271](/filings/0000009326-26-000018.md) | [284](/filings/0000009326-26-000028.md) | [291](/filings/0000009326-26-000035.md) |
| Cost of revenue | $m | [154 d](/filings/0000009326-26-000007.md) | [158](/filings/0001628280-25-019593.md) | [151](/filings/0000009326-25-000014.md) | [155](/filings/0000009326-25-000022.md) | [154 d](/filings/0000009326-26-000007.md) | [162](/filings/0000009326-26-000018.md) | [162](/filings/0000009326-26-000028.md) | [172](/filings/0000009326-26-000035.md) | [170 d](/filings/0000009326-26-000007.md) | [170](/filings/0000009326-26-000018.md) | [180](/filings/0000009326-26-000028.md) | [185](/filings/0000009326-26-000035.md) |
| Gross profit | $m | [75.0](/filings/0001628280-25-007202.md) | [81.5](/filings/0000009326-26-000007.md) | [83.0](/filings/0000009326-26-000007.md) | [85.4](/filings/0000009326-26-000007.md) | [86.3](/filings/0000009326-26-000007.md) | [88.2](/filings/0000009326-26-000018.md) | [93.1](/filings/0000009326-26-000028.md) | [95.5](/filings/0000009326-26-000035.md) | [93.9](/filings/0000009326-26-000007.md) | [101](/filings/0000009326-26-000018.md) | [104](/filings/0000009326-26-000028.md) | [106](/filings/0000009326-26-000035.md) |
| Research and development | $m | [3.9 d](/filings/0000009326-26-000007.md) | [4.1](/filings/0001628280-25-019593.md) | [3.9](/filings/0000009326-25-000014.md) | [4.3](/filings/0000009326-25-000022.md) | [4.5 d](/filings/0000009326-26-000007.md) | [4.7](/filings/0000009326-26-000018.md) | [4.3](/filings/0000009326-26-000028.md) | [4.5](/filings/0000009326-26-000035.md) | [5.1 d](/filings/0000009326-26-000007.md) | [5.9](/filings/0000009326-26-000018.md) | [4.5](/filings/0000009326-26-000028.md) | [5.3](/filings/0000009326-26-000035.md) |
| Operating income | $m | [38.3 d](/filings/0000009326-26-000007.md) | [41.7](/filings/0001628280-25-019593.md) | [45.8](/filings/0000009326-25-000014.md) | [48.0](/filings/0000009326-25-000022.md) | [47.4 d](/filings/0000009326-26-000007.md) | [51.0](/filings/0000009326-26-000018.md) | [51.4](/filings/0000009326-26-000028.md) | [54.6](/filings/0000009326-26-000035.md) | [52.3 d](/filings/0000009326-26-000007.md) | [55.6](/filings/0000009326-26-000018.md) | [59.2](/filings/0000009326-26-000028.md) | [62.4](/filings/0000009326-26-000035.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [6.6 d](/filings/0000009326-26-000007.md) | [7.9](/filings/0001628280-25-019593.md) | [9.2](/filings/0000009326-25-000014.md) | [10.1](/filings/0000009326-25-000022.md) | [10.9 d](/filings/0000009326-26-000007.md) | [10.9](/filings/0000009326-26-000018.md) | [10.7](/filings/0000009326-26-000028.md) | [11.8](/filings/0000009326-26-000035.md) | [10.8 d](/filings/0000009326-26-000007.md) | [12.2](/filings/0000009326-26-000018.md) | [13.2](/filings/0000009326-26-000028.md) | [13.3](/filings/0000009326-26-000035.md) |
| Net income | $m | [26.6](/filings/0001628280-25-007202.md) | [29.0](/filings/0000009326-26-000007.md) | [32.1](/filings/0000009326-26-000007.md) | [33.8](/filings/0000009326-26-000007.md) | [33.6](/filings/0000009326-26-000007.md) | [37.1](/filings/0000009326-26-000035.md) | [38.3](/filings/0000009326-26-000035.md) | [40.3](/filings/0000009326-26-000035.md) | [39.2](/filings/0000009326-26-000007.md) | [40.3](/filings/0000009326-26-000035.md) | [44.6](/filings/0000009326-26-000035.md) | [46.7](/filings/0000009326-26-000035.md) |
| Diluted EPS | $ per share | [0.82](/filings/0001628280-25-007202.md) | [0.89](/filings/0000009326-26-000007.md) | [0.98](/filings/0000009326-26-000007.md) | [1.03](/filings/0000009326-26-000007.md) | [1.03](/filings/0000009326-26-000007.md) | [1.13](/filings/0000009326-26-000018.md) | [1.17](/filings/0000009326-26-000028.md) | [1.24](/filings/0000009326-26-000035.md) | [1.21](/filings/0000009326-26-000007.md) | [1.25](/filings/0000009326-26-000018.md) | [1.39](/filings/0000009326-26-000028.md) | [1.46](/filings/0000009326-26-000035.md) |
| Basic EPS | $ per share | [0.83](/filings/0001628280-25-007202.md) | [0.90](/filings/0000009326-26-000007.md) | [0.99](/filings/0000009326-26-000007.md) | [1.05](/filings/0000009326-26-000007.md) | [1.05](/filings/0000009326-26-000007.md) | [1.14](/filings/0000009326-26-000018.md) | [1.18](/filings/0000009326-26-000028.md) | [1.25](/filings/0000009326-26-000035.md) | [1.23](/filings/0000009326-26-000007.md) | [1.26](/filings/0000009326-26-000018.md) | [1.40](/filings/0000009326-26-000028.md) | [1.47](/filings/0000009326-26-000035.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [64.4](/filings/0001628280-25-007202.md) | [60.3](/filings/0001628280-24-020268.md) | [63.7](/filings/0001628280-24-033177.md) | [73.7](/filings/0001628280-24-043795.md) | [49.5](/filings/0000009326-26-000007.md) | [49.9](/filings/0001628280-25-019593.md) | [65.4](/filings/0000009326-25-000014.md) | [65.1](/filings/0000009326-25-000022.md) | [74.6](/filings/0000009326-26-000035.md) | [72.9](/filings/0000009326-26-000018.md) | [63.2](/filings/0000009326-26-000028.md) | [66.3](/filings/0000009326-26-000035.md) |
| Current assets | $m | [314](/filings/0001628280-25-007202.md) | [325](/filings/0001628280-24-020268.md) | [320](/filings/0001628280-24-033177.md) | [326](/filings/0001628280-24-043795.md) | [314](/filings/0000009326-26-000007.md) | [340](/filings/0001628280-25-019593.md) | [365](/filings/0000009326-25-000014.md) | [344](/filings/0000009326-25-000022.md) | [366](/filings/0000009326-26-000035.md) | [389](/filings/0000009326-26-000018.md) | [388](/filings/0000009326-26-000028.md) | [405](/filings/0000009326-26-000035.md) |
| Total assets | $m | [1,597](/filings/0001628280-25-007202.md) | [1,589](/filings/0001628280-24-020268.md) | [1,575](/filings/0001628280-24-033177.md) | [1,597](/filings/0001628280-24-043795.md) | [1,575](/filings/0000009326-26-000007.md) | [1,618](/filings/0001628280-25-019593.md) | [1,678](/filings/0000009326-25-000014.md) | [1,661](/filings/0000009326-25-000022.md) | [1,686](/filings/0000009326-26-000035.md) | [1,694](/filings/0000009326-26-000018.md) | [1,687](/filings/0000009326-26-000028.md) | [1,704](/filings/0000009326-26-000035.md) |
| Current liabilities | $m | [148](/filings/0001628280-25-007202.md) | [124](/filings/0001628280-24-020268.md) | [113](/filings/0001628280-24-033177.md) | [109](/filings/0001628280-24-043795.md) | [158](/filings/0000009326-26-000007.md) | [140](/filings/0001628280-25-019593.md) | [138](/filings/0000009326-25-000014.md) | [126](/filings/0000009326-25-000022.md) | [176](/filings/0000009326-26-000035.md) | [153](/filings/0000009326-26-000018.md) | [146](/filings/0000009326-26-000028.md) | [164](/filings/0000009326-26-000035.md) |
| Total liabilities | $m | [543](/filings/0001628280-25-007202.md) | [510](/filings/0001628280-24-020268.md) | [463](/filings/0001628280-24-033177.md) | [420](/filings/0001628280-24-043795.md) | [425](/filings/0000009326-26-000007.md) | [409](/filings/0001628280-25-019593.md) | [410](/filings/0000009326-25-000014.md) | [363](/filings/0000009326-25-000022.md) | [429](/filings/0000009326-26-000035.md) | [409](/filings/0000009326-26-000018.md) | [385](/filings/0000009326-26-000028.md) | [377](/filings/0000009326-26-000035.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [1,054](/filings/0000009326-26-000007.md) | [1,079](/filings/0000009326-25-000022.md) | [1,112](/filings/0000009326-25-000022.md) | [1,177](/filings/0000009326-25-000022.md) | [1,150](/filings/0000009326-26-000035.md) | [1,209](/filings/0000009326-26-000035.md) | [1,268](/filings/0000009326-26-000035.md) | [1,298](/filings/0000009326-26-000035.md) | [1,257](/filings/0000009326-26-000035.md) | [1,285](/filings/0000009326-26-000035.md) | [1,302](/filings/0000009326-26-000035.md) | [1,327](/filings/0000009326-26-000035.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [67.4 d](/filings/0000009326-26-000007.md) | [33.4](/filings/0001628280-25-019593.md) | [45.0 d](/filings/0000009326-25-000014.md) | [51.3 d](/filings/0000009326-25-000022.md) | [52.3 d](/filings/0000009326-26-000007.md) | [36.5](/filings/0000009326-26-000018.md) | [47.3 d](/filings/0000009326-26-000028.md) | [65.6 d](/filings/0000009326-26-000035.md) | [67.3 d](/filings/0000009326-26-000007.md) | [40.1](/filings/0000009326-26-000018.md) | [46.7 d](/filings/0000009326-26-000028.md) | [69.8 d](/filings/0000009326-26-000035.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Dividends paid | $m | [0.0 d](/filings/0000009326-26-000007.md) | [25.6](/filings/0001628280-25-019593.md) | [0.0 d](/filings/0000009326-25-000014.md) | [0.0 d](/filings/0000009326-25-000022.md) | [0.0 d](/filings/0000009326-26-000007.md) | [28.3](/filings/0000009326-26-000018.md) | [0.0 d](/filings/0000009326-26-000028.md) | [0.0 d](/filings/0000009326-26-000035.md) | [0.0 d](/filings/0000009326-26-000007.md) | [30.8](/filings/0000009326-26-000018.md) | [0.0 d](/filings/0000009326-26-000028.md) | [0.0 d](/filings/0000009326-26-000035.md) |
| Share repurchases | $m | [0.4 d](/filings/0000009326-26-000007.md) | [5.2](/filings/0001628280-25-019593.md) | [0.0 d](/filings/0000009326-25-000014.md) | [0.2 d](/filings/0000009326-25-000022.md) | [0.3 d](/filings/0000009326-26-000007.md) | [5.3](/filings/0000009326-26-000018.md) | [33.3 d](/filings/0000009326-26-000028.md) | [15.4 d](/filings/0000009326-26-000035.md) | [53.6 d](/filings/0000009326-26-000007.md) | [15.7](/filings/0000009326-26-000018.md) | [28.8 d](/filings/0000009326-26-000028.md) | [27.4 d](/filings/0000009326-26-000035.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [32.4](/filings/0001628280-24-020268.md) | [32.4](/filings/0001628280-24-033177.md) | [32.5](/filings/0001628280-24-043795.md) | [32.6](/filings/0001628280-25-019593.md) | [32.6](/filings/0000009326-25-000014.md) | [32.8](/filings/0000009326-25-000022.md) | [32.8](/filings/0000009326-26-000018.md) | [32.7](/filings/0000009326-26-000028.md) | [32.6](/filings/0000009326-26-000035.md) | [32.3](/filings/0000009326-26-000018.md) | [32.2](/filings/0000009326-26-000028.md) | [32.0](/filings/0000009326-26-000035.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 31,777,324 at 2026-10-15, from the cover of the [10-Q filed 2026-10-23](/filings/0000009326-26-000035.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:17 ET. No prices; not investment advice.